Arvinas, Inc. (NASDAQ:ARVN) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arvinas Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Arvinas Inc. (ARVN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 6,726,491 | $128,946,832 | 4.87% | |
| 2. | Citadel Investment Group Ken Griffin | 3,072,668 | $58,903,045 | +14% | 0.01% |
| 3. | Opaleye Management James A. Silverman | 1,625,000 | $33,643,350 | +30% | 5.88% |
| 4. | Avidity Partners Management David Witzke And Michael Gregory | 1,358,000 | $26,032,860 | -10% | 2.55% |
| 5. | Boxer Capital Aaron Davis And Christopher Fuglesang | 1,058,614 | $20,293,630 | 1.72% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.00 | 142,857 | Director | 822,857 | 2020-12-18 | Filing | |
| $23.99 | 8,333 | Director | 42,718 | 2020-11-09 | Filing | |
| $30.26 | 2,000 | Director | 79,546 | 2020-06-17 | Filing | |
| $32.30 | 3,000 | Director | 77,546 | 2020-06-02 | Filing | |
| $38.18 | 2,500 | Director | 29,520 | 2020-03-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.69 | 231 | Officer | 8,040 | 2024-11-07 | Filing | |
| $17.05 | 229 | Officer | 8,271 | 2023-11-08 | Filing | |
| $47.05 | 5,196 | Officer, Director | 1,036,681 | 2024-02-23 | Filing | |
| $47.05 | 1,702 | Officer | 181,916 | 2024-02-23 | Filing | |
| $47.05 | 1,699 | Officer | 67,516 | 2024-02-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,062,561 | $135,389,295 | 0% | |
| 2. | 6,566,145 | $125,872,999 | 0% | |
| 3. | 3,457,815 | $66,286,314 | 2.55% | |
| 4. | 3,334,308 | $63,918,684 | 0.96% | |
| 5. | 2,389,600 | $45,808,632 | 0.88% |
News See All
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
10 Best Small-Cap Stocks Ready To Explode
On October 7, Chuck Royce, founder and Senior Advisor, and Francis Gannon, Co-Chief Investment Officer and Managing Director of Royce Investment, discussed the outperformance of small-cap stocks.
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I'd like to welcome everyone to Arvinas Third Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise.
8 Best Small-Cap Growth Stocks to Buy According to Analysts
During the third quarter of 2024, small-cap stocks represented by the Russell 2000 Index made a strong comeback after a somewhat disappointing second quarter.
10 Best Small-Cap Healthcare Stocks To Buy Now
In difficult economic times, healthcare equities are sometimes regarded as a defensive investment.
Top 10 Small-Cap Stocks with Highest Upside Potential
Most giant companies start as small-cap, but by continuously developing and growing their earnings, their share price increases making them large or mega-cap companies, and along the way smart investors...
12 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the 12 most promising cancer stocks according to analysts.
Wall Street Analysts Trim Price Targets for These 10 Stocks
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts.
5 Stocks with Biggest Upside Potential According to Analysts
In this article, we will take a look at the 5 stocks with biggest upside potential according to analysts.
Billionaire Hedge Funds
